Research progress on targeted therapy combined with immune-acti-vating strategies in CLDN18.2-positive gastric cancer
10.12092/j.issn.1009-2501.2025.02.001
- VernacularTitle:靶向结合免疫激活治疗CLDN18.2阳性胃癌的研究进展
- Author:
Yang NIE
1
;
Yue WANG
1
;
Jia WEI
1
Author Information
1. 南京大学医学院附属鼓楼医院肿瘤中心,南京 210008,江苏
- Publication Type:Journal Article
- Keywords:
gastric cancer;
Claudin18.2;
tumor immune microenvironment;
targeted therapy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(2):146-158
- CountryChina
- Language:Chinese
-
Abstract:
Claudin 18 isoform 2(Claudin18.2,CLDN18.2)is a crucial structural protein involved in cell-cell tight junctions.While its expression is limit-ed in normal tissues,it is specifically overexpressed in malignant tumors such as gastric cancer,pancre-atic cancer,and esophageal cancer,making it a promising therapeutic target for cancer treatment.Recent advances in CLDN18.2-targeted therapies have been encouraging,and studies suggest that CLDN18.2-positive gastric cancer may possess a unique immune microenvironment.This raises the potential for combining targeted therapies with im-mune activation to achieve synergistic effects,po-tentially improving treatment outcomes for pa-tients with advanced gastric cancer.This review will focus on the immune microenvironment character-istics of CLDN18.2-positive gastric cancer and sum-marize the current research and clinical trial prog-ress in targeted therapies combined with immune activation for this specific cancer type.
